Dr Peush Bajpai

Dr. Peush Bajpai is a highly experienced Medical Oncologist with extensive expertise in managing complex solid and hematologic cancers. He has led oncology departments at leading hospitals in Delhi and Gurgaon, specializing in precision oncology, immunotherapy, and evidence-based cancer care. His clinical approach integrates advanced biomarkers, targeted therapies, and molecular tumor board practices to deliver personalized treatment plans. With multiple national and international certifications and numerous research publications, he is recognized for his academic contributions and leadership in modern oncology.

Educational Qualifications:

• MBBS – Baba Raghav Das Medical College, Gorakhpur (2002)
• MD (Internal Medicine) – GSVM Medical College, Kanpur (2007)
• DM (Medical Oncology) – Cancer Institute, WIA, Chennai (2012)
• ECMO Certification – European Society for Medical Oncology (2012)

Professional Experience:

• Director & Unit Head – Medical Oncology, Max Hospital, Dwarka (Current)
• HOD – Medical & Hemato-Oncology, Manipal Hospital, Dwarka (2018–2025)
• Senior Consultant – Medical Oncology, Max Hospital Shalimar Bagh (2015–2018)
• Consultant – Medical Oncology, BLK-Max Super Speciality Hospital (2012–2015)

Awards & Achievements:

• Certification – Healthcare Management, Indian School of Business (2023)
• Advanced Course – Prostate Cancer, National Cancer Institute, Singapore (2018)
• ESMO Preceptorships – Lung, Gastric & Prostate Cancers (2012)
• Advanced Course – Tropical Medicine, University of Rostock, Germany (2004)

Professional Memberships:

• European Society of Medical Oncology (ESMO)
• American Society of Clinical Oncology (ASCO)
• Indian Society of Medical & Paediatric Oncology (ISMPO)
• Indian Cooperative Oncology Network (ICON)
• NCR Oncology Group
• Indian Medical Association, Dwarka

Research Papers & Publications:

• “Management of Metastatic Colorectal Cancer (mCRC): RealWorld Recommendations”, South Asian Journal of Cancer (2024)
• “Collusion: The facade and its implications on total pain management in palliative care”, Indian Journal of Palliative Care (2022)
• “Cancer awareness among nurses in a tertiary care hospital in North Delhi, India”, International Journal of Community Medicine and Public Health (2019)
• “Panitumumab monotherapy is active in relapsed and refractory metastatic gastroesophageal adenocarcinoma and is a possible candidate for rechallenge”, Journal of Gastrointestinal Cancer (2019)
• “Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that progressed on chemotherapy”, Indian Journal of Medical and Paediatric Oncology (2018)
• “Incidence of neutropathy with weekly paclitaxel and role of oral glutamine supplementation: A prospective observational study”, Indian Journal of Medical and Paediatric Oncology (2018)
• “Prolonged survival with second-line oral cyclophosphamide therapy in a patient with non-seminomatous extragonadal germ cell tumour: A rare case series”, Indian Journal of Cancer (2015)
• Novel combinations of docetaxel, bicalutamide, and zoledronic acid in hormone-resistant prostate cancer”, Indian Journal of Cancer (2012)
• “Methotrexate-induced acute encephalopathy—occurrence on low-dose intrathecal methotrexate”, Indian Journal of Hematology and Blood Transfusion (2012)
• “Rare case of hairy cell leukaemia in a patient of head and neck malignancy”, The Tamil Nadu Dr. M.G.R. Medical University, Journal of Medicine (2011)